Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/10—Cells modified by introduction of foreign genetic material
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2510/00—Genetically modified cells
  • C12N2510/02—Cells for production
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/10011—Adenoviridae
  • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
  • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14151—Methods of production or purification of viral material
  • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
  • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
  • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
  • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
  • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2840/00—Vectors comprising a special translation-regulating system
  • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
  • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

• the present invention relates to producer cells for producing adeno-associated virus.
• the present invention further relates to a method for producing the above producer cell and a method for producing an adeno-associated virus using the producer cell.
• Adeno-associated virus (also referred to as AAV) is a linear single-stranded DNA virus that belongs to the Parvoviridae family.
• the wild-type AAV genome contains regulatory genes for replication (Rep genes) and structural genes for the capsid (Cap genes), flanked by inverted terminal repeats (ITRs) for viral replication and packaging.
• AAV vectors are capable of gene introduction into either proliferating or non-proliferating cells, and are particularly capable of long-term expression in non-dividing cells. AAV is also considered non-pathogenic and has low immunogenicity. Based on the above, clinical applications of AAV vectors as vectors for gene therapy are progressing.
• AAV is a non-enveloped virus that multiplies in the presence of helper viruses such as adenovirus and herpesvirus.
• helper viruses such as adenovirus and herpesvirus.
• AAV replication was classically performed by co-infecting host cells with an adenovirus.
• the gene responsible for the helper action of adenovirus has been identified, and plasmids carrying this gene are also in use.
• packaging into recombinant AAV can be achieved by simultaneously transfecting HEK293 cells with a plasmid containing the Rep gene and Cap gene, an adenovirus helper plasmid, and a plasmid containing the target gene (transgene). can.
• Patent Document 1 describes a nucleic acid molecule encoding a viral helper gene under the control of a first repressible promoter and a nucleic acid molecule encoding an AAV gene under the control of a second repressible promoter. , and nucleic acid molecules encoding repressor elements of first and second derepressible promoters to produce AAV.
• U.S. Pat. No. 5,020,202 describes a host cell comprising a nucleic acid encoding the adeno-associated virus REP proteins REP78 and REP68, wherein the internal AAV promoter p19 is mutated by one or more mutations that maintain the functionality of the REP78 and REP68 proteins. Host cells are described that have been inactivated.
• Patent Document 2 describes a method of inactivating internal AAV promoter p19 as a method for avoiding cytotoxicity caused by REP protein, but does not describe the production of producer cells.
• An object of the present invention is to provide a producer cell for AAV production in which cell damage during establishment of a cell line is avoided or suppressed.
• a further object of the present invention is to provide a method for producing the above-mentioned producer cells, and a method for producing adeno-associated virus using the above-mentioned producer cells.
• the present inventors found that the Cap gene under the control of a foreign promoter and the Rep gene under the control of a foreign promoter were used, and the VA-RNA gene and the E4 gene were used.
• the present invention was completed based on the above findings.
• ⁇ 1> Has a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter in its chromosome, A producer cell that does not contain at least one of the VA-RNA gene and the E4 gene and is a mammalian cell.
• ⁇ 2> The producer cell according to ⁇ 1>, wherein the foreign promoter of the Rep gene and the foreign promoter of the Cap gene are the same promoter.
• ⁇ 3> The producer cell according to ⁇ 1>, wherein the Rep gene is present downstream in the transcription direction of the Cap gene.
• ⁇ 4> The producer cell according to ⁇ 1>, which has the E4 gene under the control of a foreign promoter in its chromosome and does not contain the VA-RNA gene.
• ⁇ 5> The producer cell according to ⁇ 4>, wherein the E4 gene is downstream of IRES.
• ⁇ 6> The producer cell according to ⁇ 4>, wherein the foreign promoter of the E4 gene is an inducible promoter that can be switched on and off.
• ⁇ 7> The producer cell according to ⁇ 6>, wherein the foreign promoter of the E4 gene is a promoter whose expression can be induced by a drug.
• ⁇ 8> The producer cell according to ⁇ 7>, wherein the foreign promoter of the E4 gene is downstream of the tetracycline response element.
• ⁇ 9> The producer cell according to ⁇ 1>, which does not contain both the VA-RNA gene and the E4 gene.
• ⁇ 11> The producer cell according to ⁇ 10>, wherein the E2A gene is downstream of IRES.
• ⁇ 12> The producer cell according to ⁇ 10>, wherein the E2A gene is under the control of a foreign promoter.
• ⁇ 13> The producer cell according to ⁇ 12>, wherein the E2A gene is under the control of a cytomegalovirus-derived promoter.
• ⁇ 14> The producer cell according to ⁇ 10>, wherein the foreign promoter of the E2A gene is an inducible promoter that can be switched on and off.
• ⁇ 15> The producer cell according to ⁇ 14>, wherein the foreign promoter of the E2A gene is a promoter whose expression can be induced by a drug.
• ⁇ 16> The producer cell according to ⁇ 15>, wherein the foreign promoter of the E2A gene is downstream of the tetracycline response element.
• a producer cell is a mammalian cell that does not contain the VA-RNA gene.
• ⁇ 20> The producer cell according to ⁇ 19>, wherein one or more of the exogenous promoter of the Cap gene and the exogenous promoter of the Rep gene is a promoter whose expression can be induced by a drug.
• ⁇ 21> The producer cell according to ⁇ 20>, wherein one or more of the exogenous promoter of the Cap gene and the exogenous promoter of the Rep gene is downstream of the tetracycline response element.
• ⁇ 22> The producer cell according to any one of ⁇ 1> to ⁇ 21>, further comprising a SmallRep gene under the control of an exogenous promoter.
• ⁇ 23> The producer cell according to ⁇ 22>, wherein the Rep gene is present downstream in the transcription direction of the SmallRep gene.
• ⁇ 24> The producer cell according to ⁇ 22>, wherein the foreign promoter of the SmallRep gene is an inducible promoter that can be switched on and off.
• the foreign promoter of the SmallRep gene is a promoter whose expression can be induced by a drug.
• ⁇ 26> The producer cell according to ⁇ 25>, wherein the foreign promoter of the SmallRep gene is downstream of the tetracycline response element.
• ⁇ 27> The producer cell according to any one of ⁇ 1> to ⁇ 26>, further comprising a gene expressing a reverse tetracycline-regulated transactivator.
• ⁇ 28> The producer cell according to ⁇ 27>, wherein the gene expressing a reverse tetracycline-regulated transactivator is located downstream of the Rep gene.
• ⁇ 29> Contains the E4 gene under the control of a foreign promoter, the E2A gene under the control of a foreign promoter, and the SmallRep gene under the control of a foreign promoter, The producer cell according to ⁇ 1>, wherein the exogenous promoter of the Cap gene and the exogenous promoter of the E2 gene are the same promoter, and the exogenous promoter of the Rep gene and the exogenous promoter of the SmallRep gene are the same promoter.
• a producer cell is a mammalian cell that does not contain the VA-RNA gene, in which the Cap gene, Rep gene, and E2 gene are located nearby, but the E4 gene is not located nearby.
• a first vector carrying a Cap gene under the control of a foreign promoter, a Rep gene under the control of a foreign promoter, and an E2A gene under the control of a foreign promoter It has a second vector carrying the E4 gene under the control of a foreign promoter in its chromosome
• a producer cell is a mammalian cell that does not contain the VA-RNA gene.
• ⁇ 33> The producer cell according to ⁇ 31> or ⁇ 32>, wherein the number of E4 gene insertions on the chromosome is smaller than the number of Cap gene or E2 gene insertions on the chromosome.
• ⁇ 34> The producer cell according to ⁇ 31> or ⁇ 32>, wherein the number of E4 gene insertions on the chromosome is 0.4 times or less the number of Cap gene insertions on the chromosome.
• ⁇ 35> The producer cell according to ⁇ 31> or ⁇ 32>, wherein the number of E4 gene insertions on the chromosome is 0.4 times or less the number of E2 gene insertions on the chromosome.
• ⁇ 36> The producer according to any one of ⁇ 1> to ⁇ 35>, which comprises introducing a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter into mammalian cells.
• Cell manufacturing method ⁇ 37>
• a method for producing an adeno-associated virus comprising producing an adeno-associated virus by culturing the producer cell according to any one of ⁇ 1> to ⁇ 35>.
• ⁇ 39> A step of culturing the producer cell according to any one of ⁇ 1> to ⁇ 35> under conditions that do not induce the expression of Cap gene and Rep gene to proliferate the producer cell, and the proliferated producer cell. producing an adeno-associated virus by culturing the cells under conditions that induce expression of the Cap gene and the Rep gene; Method for producing adeno-associated virus.
• ⁇ 40> A step of culturing the producer cell according to any one of ⁇ 4> to ⁇ 8> under conditions that do not induce the expression of the Cap gene, Rep gene, and E4 gene to proliferate the producer cell, and A step of producing an adeno-associated virus by culturing the proliferated producer cells under conditions that induce expression of the Cap gene, Rep gene, and E4 gene, Method for producing adeno-associated virus.
• ⁇ A> An adeno-associated virus produced by the method for producing an adeno-associated virus according to any one of ⁇ 38> to ⁇ 40>.
• ⁇ B> A first vector carrying a Cap gene under the control of a foreign promoter, a Rep gene under the control of a foreign promoter, and an E2A gene under the control of a foreign promoter;
• cell damage during establishment of producer cells can be avoided or reduced.
• FIG. 1 shows the results of transfecting Rep and Cap genes into cells and evaluating the expression of REP and CAP.
• FIG. 2 shows the results of introducing the Rep gene and Cap gene under the control of a foreign promoter into cells and evaluating the ability to produce AAV.
• FIG. 3 shows the results of evaluating the expression of REP and CAP after introducing the Rep gene and Cap gene into cells and inducing the expression by adding doxycycline.
• FIG. 4 shows the results of Western blotting using an anti-E2 antibody and GFP observation for cells into which the E2 gene and the GFP (green fluorescent protein) gene were introduced.
• FIG. 5 shows the results of introducing the Rep gene and the Cap gene into cells having the E2 gene and the GFP gene, and evaluating the AAV production ability of the obtained cells.
• FIG. 6 shows an overview of Experiment 6.
• Figure 7 shows the results of AAV quantification for producer cell lines selected using the neomycin resistance gene as a selection marker.
• Figure 8 shows the results of AAV quantification for producer cell lines selected using RFP (red fluorescent protein) as a selection marker.
• Figure 9 shows a microscopic view of the producer cell line.
• FIG. 10 shows a schematic diagram of the gene design of Experiment 7. GOI indicates the GFP gene.
• FIG. 11 shows an overview of Experiments 7 and 8.
• FIG. 12 shows the results of AAV quantification for the highest titer strains of each design among HEK293 containing the sequences of designs 1 to 6 in their chromosomes.
• FIG. 13 shows the results of quantifying the number of Rep, Cap, E2, and E4 genes on the chromosome for multiple HEK293 clones established using the vector set of Design 4 of Experiment 7.
• FIG. 14 shows the results of quantifying the number of Rep, Cap, E2, and E4 genes on the chromosome for multiple HEK293 clones established using the vector of Design 5 of Experiment 7.
• FIG. 15 shows the results of AAV quantification for the HEK293 cell line containing the sequence of Design 4 in its chromosome and the HEK293 cell line containing the sequence of Design 5 in its chromosome, which have been adapted to suspension culture.
• a numerical range indicated using " ⁇ " means a range that includes the numerical values listed before and after " ⁇ " as the minimum and maximum values, respectively.
• Promoter refers to a sequence that drives gene expression and refers to a DNA control region/sequence that is capable of binding RNA polymerase and is involved in the initiation of transcription of downstream coding or non-coding sequences.
• foreign promoter is meant a promoter that does not contain the wild-type AAV gene. Specifically, it is a promoter that is not known to express AAV genes in nature.
• a selectable marker refers to a gene for selecting cells that actively express a nucleic acid sequence. Suitable selectable markers include genes encoding antibiotic resistance, such as kanamycin, neomycin, puromycin, hygromycin, blasticidin, or zeocin.
• Another example of a suitable selectable marker is a fluorescent protein, such as green fluorescent protein (GFP), red fluorescent protein (RFP) or blue fluorescent protein (BFP).
• a vector is a DNA or RNA molecule that is used to artificially transport a foreign gene to another cell.
• a vector for expressing a gene is called an expression vector.
• the foreign gene is replicated and/or expressed within the cell.
• Vectors include episomal (eg, plasmid) vectors and non-episomal vectors. Vectors can be introduced into host cells by methods such as transfection, transduction, cell fusion and lipofection, and electroporation.
• Loading means that another nucleic acid sequence is integrated into a chromosome or nucleic acid sequence.
• the gene is not limited as long as it has a base sequence, but it is preferably one that has a function in vivo.
• it may be a nucleotide encoding a polypeptide, or a nucleic acid molecule such as cDNA or genomic DNA.
• Producer cells are cells that can produce rAAV without requiring additional helper functions such as helper gene introduction or viral infection.
• it is a cell in which the Rep gene and the Cap gene have been integrated into the chromosome.
• a gene of interest eg, a desired therapeutic or prophylactic gene
• a necessary adenovirus helper gene may be integrated into the chromosome.
• the gene of interest may include an ITR.
• the cell may be a cell into which a gene containing a gene of interest has been integrated adjacent to two AAV inverted terminal repeats (ITRs). Genes that have not been integrated into the chromosome may be loaded onto a vector and introduced into producer cells to produce rAAV.
• the producer cell may be a cell that has integrated into its chromosome a gene that expresses a factor that affects promoter activity, or it may be a cell that has integrated into its chromosome all genes for factors that affect promoter activity. good.
• the factor that acts on promoter activity is preferably a promoter-activating factor, and more preferably a reverse tetracycline regulatory factor.
• the producer cell of the present invention has a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter in its chromosome, and contains at least one of the VA-RNA gene and the E4 gene.
• they are mammalian cells.
• Experiment 4 a cell line stably containing the E2 gene and the GFP gene (target gene) was established.
• the Rep gene and Cap gene were introduced into the cell line established in Experiment 4. It was confirmed that the obtained cell line was capable of producing AAV.
• the switched Rep and Cap genes were introduced into cells. By selecting cells using drugs or fluorescence as indicators, cell lines stably containing the Rep gene and Cap gene were established. It was confirmed that the obtained cell line was capable of producing AAV.
• the Rep gene, Cap gene, E2 gene, and optionally the E4 gene were integrated into cells.
• cell lines stably containing the Rep gene and Cap gene were established. It was confirmed that the obtained cell line was capable of producing AAV.
• the producer cells established in Experiment 7 were suspended and cultured. It was confirmed that the suspended cells were capable of producing AAV.
• the producer cell of the present invention has a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter in its chromosome.
• the Rep gene and Cap gene the Rep gene and Cap gene of adeno-associated virus genes can be used.
• Adeno-associated virus refers to a small, replication-competent, non-enveloped virus containing single-stranded DNA of the Parvoviridae and Dependoparvovirus families.
• Serotype 2 is one of the serotypes that has been widely studied for a long time, and is known to have a very wide host range.
• Serotype 1 AAV1
• serotype 5 AAV5
• serotype 6 AAV6
• AAV1 has a high efficiency of gene introduction into muscles, liver, airways, central nervous system, etc.
• AAV5 has high efficiency of gene introduction into central nervous system, liver, retina, etc.
• AAV6 has high efficiency of gene introduction into heart, muscles, liver, etc.
• the present invention is used with serotype 2 or serotype 5. Particularly preferred is serotype 5.
• An adeno-associated virus gene refers to a gene composed of one or more nucleic acid sequences derived from one or more adeno-associated virus serotypes.
• Adeno-associated virus genes are preferably genes involved in AAV replication and packaging, and genes encoding AAV component proteins.
• the Rep and Cap genes encode proteins involved in virion replication and packaging.
• the Cap region expresses VP1, VP2, and VP3.
• the Rep gene and the Cap gene may be wild-type genes, but they may be genes that have been modified by base substitution, deletion, insertion, or addition to the wild-type genes, as long as they exhibit their original functions. May be used.
• the number of modified bases is preferably 1 to 20, more preferably 1 to 10, More preferably, the number is 1 to 3.
• the base sequences of the modified Rep gene and Cap gene preferably exhibit sequence identity of 85% or more, more preferably 90% or more, with the base sequences of the wild-type Rep gene and Cap gene. and more preferably 95% or more sequence identity, even more preferably 98% or more sequence identity.
• a vector containing the Rep gene and Cap gene can be introduced into the cell.
• the arrangement of the Rep gene and Cap gene in the vector is not particularly limited, and the Cap gene and Rep gene may be arranged in the same direction or in different directions.
• the Cap and Rep genes are placed in the vector in different orientations.
• the orientation of a certain gene means the direction from the 5' side to the 3' side, and placing it in a different direction means that the direction from the 5' side to the 3' side of a certain gene and another gene are in opposite directions on the vector. means that it is placed.
• the Rep gene and Cap gene may be placed in separate vectors.
• the Rep gene may be a viral replication protein known to those skilled in the art that is collectively required for the replication of the viral genome, or a protein that mediates AAV-2 DNA replication, such as, for example, the human herpesvirus 6 (HHV-6) Rep gene. refers to the region of the AAV genome that encodes a functional homologue thereof (known to be 1). Therefore, the coding region of the Rep gene includes at least the genes encoding AAV REP78 and REP68 (long form REP proteins) and REP52 and REP40 (short form REP proteins; also referred to as "SmallRep") or functional homologs thereof. .
• the SmallRep gene includes, for example, at least REP52 or REP40, and preferably includes both.
• Rep gene and SmallRep gene Maurer AC, Weitzman MD. Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction. Hum Gene Ther. 2020 May;31(9-10):499-511. doi: 10.1089/hum.2020.069. PMID: 32303138; PMCID : PMC7232694; and Keiya Ozawa. Gene therapy using AAV. Virus Vol. 57, No. 1, pp. 47-56, 2007: is incorporated herein by reference.
• REP68 or REP78 is required for AAV production, and REP68 and REP78 are translation products of two types of mRNA transcribed from the same gene by alternative splicing.
• REP contains at least REP68 or REP78 protein, and preferably may further contain REP52 and/or REP40.
• the coding region of the Rep gene used in the present invention may be derived from any AAV serotype, but is preferably derived from AAV2. Those derived from AAV2 include REP78 and REP68 as well as REP52 and REP40, ITR.
• Cap gene refers to the region in the AAV genome encoding the viral capsid protein known to those skilled in the art. Examples of these capsid proteins are the AAV capsid proteins VP1, VP2 and VP3.
• the Cap gene used in the present invention may be derived from any AAV serotype, but is preferably derived from AAV2 or AAV5. Particularly preferred is AAV5.
• the foreign promoter for the Cap gene is an inducible promoter that can be turned on and off.
• the foreign promoter of the Rep gene is an inducible promoter that can be switched on and off.
• a promoter that can control expression on and off depending on the presence or absence of stimulation can be used.
• Stimuli include chemical stimuli (endogenous hormone stress response, lactose, tetracycline or its derivatives (e.g., doxycycline), cumic acid, proteins (rapamycin, FKCsA, abscisic acid (ABA), etc.), tamoxifen/Cre-loxP ( Examples include, but are not limited to, a system using a Cre promoter modified so that activation can be induced by tamoxifen), a riboswitch), and physical stimulation (blue light, heat).
• the inducible promoter that can be turned on and off is preferably a promoter whose expression can be induced by a drug.
• the drug is preferably tetracycline or a derivative thereof (eg, doxycycline).
• Inducible promoters that can be switched on and off include tetracycline-responsive promoters, RU486-inducible promoters, ecdysone-inducible promoters, rapamycin-inducible promoters, and metallothionein promoters.
• a specific tetracycline-responsive promoter includes the TRE-CMV-minimal promoter, which consists of a tetracycline-responsive element and a portion of the CMV promoter. This sequence is a promoter in which a tetracycline response element and a portion of the CMV promoter are linked. This promoter is used in the Tet on/off system (manufactured by TET systems).
• An insulator is a sequence that stably controls gene transcription without being affected by surrounding sequences. It is better to place the insulator between REP and CAP. Although the insulator is not particularly limited, it is preferably 50 bp or more and 10,000 bp or less, more preferably 100 bp or more and 5,000 bp or less, particularly preferably 300 bp or more and 4,000 bp or less.
• bp base pair means a base sequence or the number of base sequences.
• IRES internal ribosome entry site
• the inducible promoter that can be switched on and off may be a Tet on/off system, which is a promoter whose expression can be regulated by tetracycline, or a Tet on system.
• the promoter additionally contains at least one tetracycline response element (Tet operon).
• Tet operon tetracycline response element
• transcription can be reversibly turned on or off in the presence of the antibiotic tetracycline or one of its derivatives (e.g., doxycycline).
• Tet repressor protein present in the cell blocks expression by binding to the Tet operator sequence introduced into the promoter. Therefore, no gene expression is observed when the Tet repressor is bound to the Tet operator sequence.
• Tet operon systems are widely available, such as the Tet operon used in the pcDNATM4/TO mammalian expression vector available from Invitrogen.
• the promoter is preferably downstream of the tetracycline response element.
• the producer cell of the invention may contain a factor that affects the activity of the promoter, preferably a factor that activates the promoter, more preferably a reverse tetracycline-regulated transactivator (rtTA).
• rtTA reverse tetracycline-regulated transactivator
• rtTA reverse tetracycline-regulated transactivator
• the gene expressing the reverse tetracycline-regulated transactivator is located downstream of the Rep gene.
• the Rep gene and the Cap gene may be driven by one and the same foreign promoter, or the Rep gene and the Cap gene may be driven by two foreign promoters that drive each gene.
• the foreign promoter of the Rep gene and the foreign promoter of the Cap gene may be promoters with the same sequence or promoters with different sequences. However, promoters with the same sequence are preferred.
• the Rep gene may exist downstream in the transcription direction of the Cap gene, or the Rep gene may exist upstream in the transcription direction of the Cap gene.
• the Rep gene is present downstream of the Cap gene in the transcriptional direction.
• the producer cell of the invention may preferably further contain a SmallRep gene under the control of an exogenous promoter.
• SmallRep genes include REP52 and REP40.
• the producer cell of the invention comprises a SmallRep gene under the control of an exogenous promoter, preferably the SmallRep gene is upstream of the Rep gene.
• the SmallRep gene is preferably an inducible promoter that can be turned on and off. Details of inducible promoters that can be turned on and off are as described herein above.
• the foreign promoter of the SmallRep gene is preferably a promoter whose expression can be induced by a drug. Details of the promoter whose expression can be induced by drugs are as described above in this specification.
• the foreign promoter of the SmallRep gene is preferably downstream of the tetracycline response element.
• the vector containing the Rep gene and Cap gene is not particularly limited as long as it is a nucleic acid, and may be circular or linear.
• artificially designed nucleic acids can be used, and plasmids are preferred.
• viral helper genes are generally used.
• Viral helper genes are non-adeno-associated viral genes to enable replication and packaging of adeno-associated viruses.
• viruses helper gene genes derived from viruses other than adeno-associated virus are used.
• Specific examples of viral helper genes include those derived from adenovirus or herpesvirus, and preferably, the viral helper gene is derived from adenovirus.
• Adenovirus refers to a non-enveloped virus having an icosahedral nucleocapsid containing double-stranded DNA, belonging to the Adenoviridae family. More than 50 adenovirus subtypes have been isolated from humans, and many additional subtypes from other mammals and birds. These subtypes belong to the family Adenoviridae and are divided into two genera: Mastoadenovirus and Aaviadenovirus. These adenoviruses are morphologically and structurally similar. However, in humans, adenoviruses exhibit different immunological properties and are classified into serotypes. Two human serotypes of adenoviruses have been intensively studied, namely Ad2 and Ad5.
• Viral helper genes derived from adenovirus include E1A, E1B, E2 (preferably E2A), E4, and VA-RNA.
• the regions of the adenovirus genome necessary for the AAV genome to be replicated and packaged into capsids to form viral virions in host cells that have all or part of the E1 region are the E2A region, the E4 region, and VA1 RNA region.
• the E2 gene includes an E2A region and an E2B region, only the E2A region can be used as the E2 gene in the present invention.
• the E4 gene includes multiple ORFs. Regarding the functions provided by the E4 region, the E4 34 kDa protein encoded by the E4 region open reading frame 6 (E4ORF6) is required for AAV replication. Therefore, only ORF6 can be used as the E4 gene in the present invention.
• the producer cell of the present invention does not contain at least one of the VA-RNA gene and the E4 gene. That is, the producer cells of the present invention include those that do not contain the VA-RNA gene but contain the E4 gene, those that contain the VA-RNA gene but not the E4 gene, and those that do not contain both the VA-RNA gene and the E4 gene. can be mentioned.
• the producer cell of the present invention has the E4 gene under the control of a foreign promoter in its chromosome and does not contain the VA-RNA gene.
• the producer cell has the Cap gene under the control of a foreign promoter, the Rep gene under the control of a foreign promoter, and the E4 gene under the control of a foreign promoter in its chromosome, and the VA-RNA gene.
• Producer cells that do not contain mammalian cells are not contain mammalian cells.
• the E4 gene is preferably located downstream of the IRES.
• the foreign promoter for the E4 gene is preferably an inducible promoter that can be turned on and off. Details of inducible promoters that can be turned on and off are as described herein above.
• the foreign promoter of the E4 gene is preferably a promoter whose expression can be induced by a drug. Details of the promoter whose expression can be induced by drugs are as described above in this specification.
• the foreign promoter of the E4 gene is preferably downstream of the tetracycline response element.
• the producer cells of the invention do not contain both the VA-RNA gene and the E4 gene. "Does not contain a certain gene” means not only that it is not contained in chromosomes, but also that it is not contained in cells.
• the producer cell of the present invention may preferably further contain an E2 gene (preferably an E2A gene).
• the E2A gene may be a wild-type gene, but it is also possible to use a wild-type gene with modifications such as base substitutions, deletions, insertions, or additions, as long as it exhibits its original function. Good too.
• the producer cell of the present invention contains an E2 (preferably E2A) gene
• the E2 gene is preferably downstream of the IRES.
• the E2 gene may be introduced as a second vector that is different from the vector containing the Rep and Cap genes.
• the number of modified bases is preferably 1 to 20, more preferably 1 to 10, and even more preferably There are 1 to 3 pieces.
• the modified E2A gene nucleotide sequence preferably exhibits sequence identity of 85% or more, more preferably 90% or more, and still more preferably, the nucleotide sequence of the wild-type E2A gene. Showing sequence identity of 95% or more, even more preferably showing sequence identity of 98% or more.
• the E2 (preferably E2A) gene may be under the control of a promoter, preferably a foreign promoter.
• the foreign promoter of the E2 (preferably E2A) gene is preferably an inducible promoter that can be switched on and off. Details of inducible promoters that can be turned on and off are as described herein above.
• the foreign promoter of the E2 (preferably E2A) gene is preferably a promoter whose expression can be induced by a drug. Details of the promoter whose expression can be induced by drugs are as described above in this specification.
• the E2 (preferably E2A) gene may be turned on and off under the control of a tetracycline-responsive promoter (TET).
• Promoters for the E2 (preferably E2A) gene include, but are not limited to, cytomegalovirus-derived promoter (CMV promoter) (including an enhancer if desired), SV40 early promoter, human elongation factor-1 ⁇ (EF-1 ⁇ ) promoter, Examples include the human ubiquitin C promoter, the retroviral Rous sarcoma virus (RSV) LTR promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerate kinase (PGK) promoter, and the tetracycline-responsive promoter.
• CMV promoter cytomegalovirus-derived promoter
• SV40 early promoter SV40 early promoter
• EF-1 ⁇ human elongation factor-1 ⁇
• Examples include the human ubiquitin C promoter, the
• tetracycline-responsive promoters and cytomegalovirus-derived promoters.
• tetracycline-responsive promoters include TRE-CMV-minimal promoter.
• the foreign promoter of the E2 (preferably E2A) gene is downstream of the tetracycline response element.
• the producer cell comprises an E4 gene under the control of a foreign promoter, an E2 (preferably E2A) gene under the control of a foreign promoter, and a SmallRep gene under the control of a foreign promoter,
• E4 gene under the control of a foreign promoter
• E2 preferably E2A
• SmallRep gene under the control of a foreign promoter
• the exogenous promoter of the Cap gene and the exogenous promoter of the E2 gene are the same promoter
• the exogenous promoter of the Rep gene and the exogenous promoter of the SmallRep gene are the same promoter.
• a vector containing the E2 (preferably E2A) gene can be introduced into the cells.
• the vector containing the E2 (preferably E2A) gene is not particularly limited as long as it is a nucleic acid, and may be circular or linear.
• E2 preferably E2A
• plasmids, artificially designed chromosomes, etc. can be used, and plasmids are preferred.
• the producer cell of the present invention may preferably further contain a gene of interest.
• a gene of interest for example, a therapeutic or prophylactic gene can be used.
• Therapeutic or prophylactic genes include genes that are incomplete or missing in the genome of the target cell or encode non-natural proteins that have the desired biological or therapeutic effect (e.g. antiviral function).
• examples of therapeutic or prophylactic genes include inflammatory diseases, autoimmunity, chronic and infectious diseases (including disorders such as AIDS, cancer, neurological diseases, cardiovascular diseases, hypercholesteremia, etc.), anemia and hematology.
• Examples include genes used for the treatment or prevention of various blood diseases such as philophilia, and gene defects (eg, cystic fibrosis, Gaucher disease, adenosine deaminase (ADA) deficiency, emphysema, etc.).
• gene defects eg, cystic fibrosis, Gaucher disease, adenosine deaminase (ADA) deficiency, emphysema, etc.
• GFP or RFP was used instead of the target gene.
• some antisense oligonucleotides are useful in antisense therapy against cancer and against viral diseases, such as short oligonucleotides complementary to sequences around the translation start site (AUG codon) of mRNA. nucleotides).
• the therapeutic or preventive gene may be linked to a promoter for expressing the therapeutic or preventive gene.
• Promoters for expressing therapeutic or preventive genes are not particularly limited, but include cytomegalovirus-derived promoters (including enhancers if desired), SV40 early promoters, human elongation factor-1 ⁇ (EF-1 ⁇ ) promoters, and human ubiquitin C. Promoters include retroviral Rous sarcoma virus LTR promoters, dihydrofolate reductase promoters, ⁇ -actin promoters, and phosphoglycerate kinase (PGK) promoters.
• PGK phosphoglycerate kinase
• a therapeutic or preventive gene and a promoter for expressing the gene are flanked by ITR sequences.
• the inverted terminal sequence is a base sequence for integrating the adeno-associated virus gene into target cells. There are usually two opposite terminal sequences located on both sides of the target gene.
• the reverse terminal sequence is preferably, but not limited to, a sequence derived from serotype 2 AAV.
• the producer cell of the present invention is preferably a eukaryotic cell, such as a mammalian cell or an insect cell.
• the cells are more preferably mammalian cells. Examples of mammalian cells include, but are not limited to, human cells, mouse cells, rat cells, monkey cells, and hamster cells. Preferably human cells can be used.
• cells examples include HEK293 (human embryonic kidney) cells, mouse myeloma (NSO) cell line, Chinese hamster ovary (CHO) cell line, HT1080, H9, HepG2, MCF7, MDBK Jurkat, NIH3T3, PC12, BHK ( infant hamster kidney cells), VERO, SP2/0, YB2/0, Y0, C127, L cells, COS (e.g. COS1 and COS7), QC1-3, VERO, PER. C6, HeLa, EB1, EB2, EB3, hybridoma cell lines.
• the cells are HEK293 cells.
• the producer cell of the present invention has a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter in its chromosome.
• the producer cell of the present invention has in its chromosome a vector containing a Cap gene under the control of a foreign promoter and a vector containing a Rep gene under the control of a foreign promoter.
• Being in a chromosome means that the entire length or part of the vector is integrated into the chromosome.
• Preferred embodiments of the producer cells of the present invention include: The VA- A mammalian cell that does not contain an RNA gene, in which the Cap gene, Rep gene, and E2 gene are present in the vicinity (for example, at the same locus), and the E4 gene is not present in the vicinity (for example, at the same locus); and A first vector carrying a Cap gene under the control of a foreign promoter, a Rep gene under the control of a foreign promoter, an E2A gene under the control of a foreign promoter, and an E4 gene under the control of a foreign promoter.
• Producer cell which is a mammalian cell that has a second vector loaded in its chromosome and does not contain the VA-RNA gene: can be mentioned.
• the number of E4 gene insertions on the chromosome is preferably smaller than the number of other genes insertions. This is because the toxicity of E4 causes a decrease in cell survival, and the fewer the number of E4 gene insertions, the easier the cells will survive.
• the number of E4 gene insertions on the chromosome is preferably smaller than the number of Cap gene or E2 gene insertions on the chromosome. More preferably, the number of E4 gene insertions on the chromosome is 0.8 times or less, even more preferably 0.6 times or less, the number of Cap gene or E2 gene insertions on the chromosome, and 0.
• the lower limit of the number of E4 gene insertions on the chromosome is preferably 0.01 times or more, more preferably 0.02 times or more, and 0.03 times the number of Cap genes or E2 genes inserted on the chromosome. The above is more preferable.
• the producer cell of the present invention can be produced by introducing a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter into a mammalian cell. That is, the method for producing producer cells according to the present invention is a method that includes introducing into a mammalian cell a Cap gene under the control of a foreign promoter and a Rep gene under the control of a foreign promoter.
• Preferred embodiments of the combination of vectors used in producing the producer cells of the present invention include the following embodiments.
• Vector containing Rep gene and Cap gene vector containing E2 (preferably E2A) gene, and vector containing desired therapeutic or preventive gene
• the vector containing the Cap gene under the control of a foreign promoter and the vector containing the Rep gene under the control of a foreign promoter only need to be introduced so that they are expressed, but in the present invention, the vector contains the Cap gene under the control of a foreign promoter. Integration into the chromosome preferably results in permanent expression. Permanent expression means that when a cell divides, the vector containing the Cap gene under the control of the foreign promoter and the Rep gene under the control of the foreign promoter will also be replicated, and the cell after division will also have the vector. It means becoming.
• a vector containing the Cap gene under the control of a foreign promoter and a vector containing the Rep gene under the control of a foreign promoter can be integrated into the chromosome by transfection or transduction. Furthermore, by using it in combination with the transposon method, it can be integrated into the chromosome with high efficiency.
• Transfection refers to changing the membrane of a eukaryotic cell by chemical means (e.g., calcium phosphate-mediated precipitation or lipofection), mechanical means (e.g., electroporation), or physical means (e.g., bioballistic delivery). This refers to the transverse introduction of nucleic acids into cells. Lipofection is the process of forming a complex between a vector and a positively charged lipid through electrical interaction, and introducing a nucleic acid into cells through endocytosis or membrane fusion.
• chemical means e.g., calcium phosphate-mediated precipitation or lipofection
• mechanical means e.g., electroporation
• physical means e.g., bioballistic delivery
• Transduction refers to the introduction of nucleic acids into cells by crossing the membrane of eukaryotic cells via a virus-derived vector.
• the method for producing a producer cell of the present invention may include introducing a gene expression regulatory factor, and may further include introducing a reverse tetracycline-regulated transactivator.
• Introduction of the reverse tetracycline-regulated transactivator can be carried out by introducing a vector containing a gene encoding the reverse tetracycline-regulated transactivator into cells by methods such as transfection, transduction, and lipofection. can.
• adeno-associated virus can be produced by culturing the producer cells of the present invention. That is, the method for producing adeno-associated virus of the present invention includes producing adeno-associated virus by culturing the producer cell of the present invention.
• the producer cells of the present invention are cultured under conditions that do not induce the expression of the Cap gene and the Rep gene to proliferate the producer cells, and then the proliferated producer cells are
• the step of producing adeno-associated virus can be carried out by culturing under conditions that induce the expression of adeno-associated virus.
• the producer cell of the present invention which has the E4 gene under the control of a foreign promoter in its chromosome and does not contain the VA-RNA gene, is produced under conditions that do not induce the expression of the Cap gene, Rep gene, and E4 gene.
• the condition in which the expression of the Cap gene and Rep gene is not induced in the producer cell of the present invention means that the inducible promoter controls the Cap gene and Rep gene, and the expression thereof is turned off, and is preferably Its expression is controlled by a drug, meaning that the producer cell is not contacted with a drug that turns on the inducible promoter, and more preferably, that a tetracycline drug is not contacted with the producer cell.
• Conditions that induce expression of the Cap gene and Rep gene mean that an inducible promoter controls the Cap gene and Rep gene, and their expression is on, and preferably the expression is controlled by a drug.
• the producer cells are cultured under conditions that do not induce the expression of Cap genes and Rep genes, and after performing a step of growing for 3 days or more, the grown producer cells are grown under conditions that induce the expression of Cap genes and Rep genes.
• the step of producing adeno-associated virus can be carried out by culturing under the following conditions. It is preferable to culture for 3 days or more, more preferably for 5 days or more, and even more preferably for 7 days or more under conditions that do not induce the expression of Cap gene and Rep gene.
• AAV can be produced if it contains a gene that expresses a transactivation factor (tTA).
• tTA transactivation factor
• Cell culture in the method for producing adeno-associated virus of the present invention can be performed under normal conditions for cell culture.
• the medium and culture conditions to be used can be appropriately selected by those skilled in the art.
• the media include Expi293 Expression Medium (Thermo Fisher Scientific, A1435101), Dulbecco's modified Eagle medium (DMEM) containing 10% (vol/vol) fetal bovine serum (FBS), and serum-free UltraCUL. TURE (trademark) medium (Lonza) etc. can be used, but is not particularly limited.
• the culture temperature is generally 25°C to 45°C, preferably 30°C to 42°C, more preferably 35°C to 40°C, and one example is 37°C.
• the CO 2 concentration is generally 3-10% CO 2 , preferably 5-10% CO 2 , one example being 8% CO 2 .
• Cells can be cultured in any volume of medium, for example, cells can be cultured in 1 mL to 2000 L of medium, preferably 1 L to 2000 L, more preferably 50 L to 2000 L, and 500 L to 2000 L. Particularly preferred. Cultivation may be performed while shaking and stirring.
• the stirring speed for shaking and stirring is generally 50 rpm to 200 rpm, preferably 80 to 150 rpm.
• the agitation culture may be a rotation agitation culture using a propeller or the like in a reactor.
• the stirring speed in the case of rotary stirring is generally 50 rpm to 200 rpm, preferably 80 to 150 rpm.
• stirring may be performed by wave-type shaking stirring or vertical movement of stirring blades, but there is no particular limitation.
• the culture time in the AAV production step is not particularly limited, but is generally 6 hours to 14 days, preferably 12 hours to 7 days, more preferably 24 hours to 144 hours, and even more preferably 24 hours. hours to 96 hours.
• the titer of the adeno-associated virus produced can be determined by conventional methods known to those skilled in the art. For example, the cell culture solution after culturing is collected, the cells are disrupted by freezing and thawing, and then the supernatant is collected by centrifugation. By adding MgCl 2 and Benzonase to the collected supernatant and performing a reaction, gDNA (genomic DNA) and remaining plasmids can be digested. It is possible to measure the titer of AAV by using the sample containing adeno-associated virus obtained above as a ddPCR (Droplet Digital PCR) sample and performing ddPCR.
• ddPCR Droplet Digital PCR
• AAVpro registered trademark
• AAV5 Helper Free System
• SEQ ID NO: 1 SEQ ID NO: 2
• SEQ ID NO: 3 SEQ ID NO: 3
• the entire sequences of the plasmids used are shown in SEQ ID NOs: 4 to 14 in the sequence listing. The sequence was manufactured by total synthesis method.
• ⁇ Gene introduction method> Mix equal amounts of 36 ⁇ L of Polyethylenenimine (PEI) (PolyPlus-transfection SAS, 115-0015) and plasmids of the combinations described below in 1.8 mL of Expi293 Expression Medium, suspend the total amount of 18 ⁇ g, and let stand for 15 minutes. I placed it. Thereafter, the above reagent was added to cultured cells (culture solution volume: 12 mL) that had been seeded the previous day at a cell concentration of 1 x 10 7 cells/mL, and incubated at 37° C. and 8% CO 2 conditions.
• PEI Polyethylenenimine
• anti-mouse IgG-HRP (Cytiva) diluted 10,000 times with a blocking solution was reacted at room temperature for 2 hours, and then SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher REP protein by Scientific, 34095) and capsid structural proteins (VP1, VP2, VP3) were detected.
• WSE-6100 LuminoGraph I (Ato, 2006100) was used for photography. Quantitative evaluation was performed using ImageJ for analysis of the acquired images.
• ⁇ AAV titer measurement> The HEK cell culture medium cultured at 37°C and 8% CO 2 for 72 hours after gene introduction was collected, and the cells were disrupted by freezing and thawing at -80°C. Thereafter, the supernatant was collected by centrifugation at 13,800 x g, and 25 U/mL Benzonase at a final concentration of 2 mmol/L MgCl 2 was added, and the reaction was performed at 37°C for 2 hours to remove gDNA (genomic DNA) and remaining plasmids. digested.
• ddPCR Droplet Digital PCR
• the ddPCR sample was diluted 50 times with TE buffer (pH 8.0, containing 0.05% Pluronic F-68 and 10 ⁇ g/mL calf thymus DNA).
• droplets are formed from the prepared solution using a droplet forming device, denatured at 95°C for 10 minutes (preheating), 30 seconds at 94°C (denaturation), and then denatured at 55°C for 60 seconds (annealing and extension). Annealing and extension were performed for 40 cycles, followed by incubation at 98°C for 10 minutes. Measurement was performed using a droplet reader, and AAV genome titer (vg/mL) was calculated.
• ⁇ Cell line establishment> Mix equal amounts of 36 ⁇ L of Polyethylenenimine (PEI) (PolyPlus-transfection SAS, 115-0015) and plasmids of the combinations described below in 1.8 mL of Expi293 Expression Medium, suspend in a total amount of 18 ⁇ g, and let stand for 15 minutes. I did. Thereafter, the above reagent was added to cultured cells (culture solution volume: 12 mL) that had been seeded the previous day at a cell concentration of 1 x 10 7 cells/mL, and incubated at 37° C. and 8% CO 2 conditions.
• PEI Polyethylenenimine
• the gene-introduced cells were maintained and cultured for 3 weeks, and single cells positive for RFP or GFP fluorescence were isolated using drug selection using resistance genes or flow cytometry.
• the isolated cells were suspended in DMEM containing 10% fetal bovine serum and cultured on a 6-well plate at 37° C. and 8% CO 2 for one month to establish a cell line.
• Doxycycline (DOX) at a final concentration of 0.5 ⁇ g/mL was added to the DOX (+) sample after gene introduction.
• AAV genome titers extracted from HEK293 cells cultured for 72 hours after addition of doxycycline were evaluated.
• kits (Takara, etc.) generally use three types of plasmids, and the various genes contained in these plasmids interact with each other. Therefore, if the E4 gene and VA-RNA gene are not used, REP and CAP cannot be expressed and AAV cannot be produced.
• SEQ ID NO: 9 was prepared and the gene was introduced simultaneously with SEQ ID NO: 10, doxycycline (DOX) was added 24 hours after the gene introduction, and 72 hours later, the expression of REP protein and CAP protein was evaluated by Western blotting.
• DOX doxycycline
• rtTA(-), DOX(-) Condition without TET regulator and inducer (assess gene expression leak when switch OFF) rtTA (+), DOX (-): with TET regulator / without inducer (evaluate gene expression leak when switch OFF) rtTA(+), DOX(+): Condition in which TET regulator and inducer are present (evaluation of gene expression at switch ON) rtTA is a protein that expresses a gene under the control of the TRE-CMV-minimal promoter, and was introduced as a plasmid. CMV-minimal promoter was used as the rtTA promoter.
• Experiment 4 Production of E2 gene and GFP inserted cells ⁇ Method> Lentiviral High Titer Packaging Mix (Takara) and SEQ ID NO: 11 or SEQ ID NO: 12 were introduced together into HEK293T cells (Takara) to produce lentivirus.
• the culture supernatant was added to 1/100 volume of HEK293 cells along with 2 to 12 ⁇ g/ml of polybrene to establish infected cells. Therefore, a drug was added to the cells, and the genomes were extracted from those that had been passaged for more than one month, and the insertion of the E2 gene and GFP gene into the chromosome was confirmed by PCR. Whether the protein was expressed was detected by Western Blot (E2 antibody) for E2. Furthermore, the presence of green fluorescence in GFP was confirmed using a fluorescence microscope.
• E2 antibody Western Blot
• Figure 4 shows Western blot using anti-E2 antibody ((lower left figure in Figure 4) and GFP observation (fluorescence microscope) (lower right figure in Figure 4) for stable expression lines (proliferated cells). The results are shown below. A stable strain was established in which GFP sandwiched between ITRs was inserted as the target gene, and a stable strain was established in which E2 driven under the CMV promoter was inserted.
• the selected cell lines (30 strains introduced with SEQ ID NO. 14 and 60 strains introduced with SEQ ID NO. 13) were seeded at 300,000 cells/well, and doxycycline was added to induce gene expression. After 72 hours, AAV was quantified by ddPCR.
• Figure 7 shows the results of AAV quantification for the strain into which SEQ ID NO: 14 (selection marker: NEO neomycin resistance gene) was introduced.
• the vertical axis shows AAV Titer vg/cell, and the horizontal axis shows Clone number.
• FIG. 8 shows the results of AAV quantification for the strain into which SEQ ID NO: 13 (selection marker: RFP red fluorescent protein) was introduced.
• the vertical axis shows AAV Titer vg/cell, and the horizontal axis shows Clone number.
• a representative micrograph of a stable strain is shown in Figure 9.
• the plasmid vector of SEQ ID NO: 27 was further co-introduced in order to improve the efficiency of recombination into the chromosomes of SEQ ID NO: 18, 19, 20, 22, 24, and 25.
• Transposase recombinant enzyme was transiently expressed.
• Design 1-introduced cells, Design 2-introduced cells, and Design 5-introduced cells were selected using green fluorescence as an index.
• Design 3-introduced cells, Design 4-introduced cells, and Design 6-introduced cells were selected by adding G418 at a concentration of 200 ⁇ g/ml, and further selected using green fluorescence as an indicator (FIG. 11).
• Genomes were extracted from cells cultured for more than one month after gene introduction, and stable strains were established by confirming the introduction into the genome using the PCR method.
• the selected cell line was seeded on a 24-well plate at 3.0 ⁇ 10 5 cells/well, and doxycycline was added to induce gene expression. After 72 hours, AAV was quantified by ddPCR.
• ddPCR sample 1.0 ⁇ 10 6 cells were collected from the selected cell line, and genomic DNA was extracted using DNeasy Blood & Tissue Kit (QIAGEN). This was used as a ddPCR sample.
• the ddPCR sample was diluted to 15 ng/ul with nuclease-free water (Thermo Fisher Scientific, 10977015). Place 10 ⁇ L of ddPCRtm Supermix for Probes (no dUTP) (BIORAD) in a tube on ice, 2 ⁇ L of diluted ddPCR sample, the combination of primers (final concentration 900 nmol/L) and probe (final concentration 250 nmol/L) shown in Table 2, and nuclease.
• SEQ ID NO: 30 used a HEK fluorescent dye-labeled DNA probe
• SEQ ID NO: 33, SEQ ID NO: 36, SEQ ID NO: 39, and SEQ ID NO: 42 used FAM fluorescent dye-labeled DNA probes.
• FIG. 12 The results of AAV quantification for the highest titer strains of Design 1 to Design 6 introduced cells are shown in FIG. 12.
• the vertical axis shows AAV Titer vg/cell
• the horizontal axis shows cell line names.
• Figures 13 and 14 show the number of gene insertions in the genome measured by the PCR method for the cell lines introduced with Design 4 (10 lines) and the cell lines introduced with Design 5 (10 lines).
• the first vertical axis shows the number of genes inserted per cell
• the second vertical axis shows AAV Titer vg/cell
• the horizontal axis shows the clone name.
• Experiment 8 Suspension of producer cells ⁇ Method> The highest titer strain of Design 4-introduced cells established in Experiment 7 and the highest titer strain of Design 5 were mixed in 12 mL of Expi293 Expression Medium (Thermo Fisher Scientific, A1435101) to a concentration of 0.1 to 2 ⁇ 10 6 cells/mL. The cells were suspended in the same manner, cultured in a 125 mL shaking flask, and suspended. The culture solution was incubated at 37° C. and 8% CO 2 while being constantly stirred at 120 rpm. The cells were continuously cultured for one month after suspension.
• the suspended cultured cell line was seeded in Expi293 Expression Medium at a density of 4.0 ⁇ 10 5 cells/mL, and doxycycline was added to induce gene expression.
• the culture solution was incubated at 37° C. and 8% CO 2 while being constantly stirred at 120 rpm. After 72 hours, AAV was quantified by ddPCR.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Virology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Plant Pathology (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• Cell Biology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=87935079

Family Applications (1)

Country Status (5)

Cited By (2)

Citations (4)

Family Cites Families (1)

• 2023
  • 2023-03-08 JP JP2024506360A patent/JPWO2023171698A1/ja active Pending
  • 2023-03-08 CN CN202380026191.6A patent/CN119278268A/zh active Pending
  • 2023-03-08 WO PCT/JP2023/008736 patent/WO2023171698A1/ja not_active Ceased
  • 2023-03-08 EP EP23766874.4A patent/EP4491717A4/en active Pending
• 2024
  • 2024-09-06 US US18/827,497 patent/US20240425826A1/en active Pending

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events